Evidence map›Paper›PMID 29404651›Full record

ReviewDer Nervenarzt2018

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

M Löbermann, B Handorn, A Winkelmann, E C Reisinger, H P Hartung, U K Zettl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M LöbermannAbteilung für Tropenmedizin, Infektionskrankheiten und Sektion Nephrologie, Zentrum für Innere Medizin, Universitätsmedizin Rostock, Ernst Heydemann Straße 6, 18057, Rostock, Deutschland. micha.loebermann@uni-rostock.de.
B HandornSimmons & Simmons LLP, München, Deutschland.
A WinkelmannZentrum für Nervenheilkunde, Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Rostock, Deutschland.
E C ReisingerAbteilung für Tropenmedizin, Infektionskrankheiten und Sektion Nephrologie, Zentrum für Innere Medizin, Universitätsmedizin Rostock, Ernst Heydemann Straße 6, 18057, Rostock, Deutschland.
H P HartungKlinik für Neurologie, UKD, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
U K ZettlZentrum für Nervenheilkunde, Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Rostock, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In June 2017 the European Court of Justice (ECJ) issued a verdict on the legal assessment of the association between hepatitis B immunization and the subsequent manifestation of multiple sclerosis (MS). This led to a high level of insecurity in the medical field as well as the normal population, especially in MS patients. The aim of this article is to briefly present the evidence-based medical facts and in particular to clearly highlight the legal aspects of the abovenamed ECJ verdict.

Indexed as

Hepatitis BMultiple SclerosisVaccinationEuropean UnionHumansBurden of proofCourt verdictHepatitis B vaccinationMedicinal products liabilityProduct liability

Identifiers

PMID29404651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.